Now showing items 1-2 of 2

    • Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine 

      Santolaya, María Elena; O'Ryan Gallardo, Miguel; Valenzuela, María Teresa; Prado, Valeria; Vergara, Rodrigo F.; Muñoz, Alma; Toneatto, Daniela; Graña, Gabriela; Wang, Huajun; Dull, Peter M. (Taylor & Francis, 2013)
      We previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero®), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. participants ...
    • Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis 

      Ruiz Palacios, Guillermo M.; Pérez Schael, Irene; Velázquez, F. Raúl; Abate, Héctor; Breuer, Thomas; Costa Clemens, SueAnn; Cheuvart, Brigitte; Espinoza, Félix; Gillard, Paul; Innis, Bruce L.; Cervantes, Yolanda; Linhares, Alexandre C.; López, Pío; Macías Parra, Mercedes; Ortega Barría, Eduardo; Richardson, Vesta; Rivera Medina, Doris Maribel; Rivera, Luis; Salinas, Belén; Pavia Ruz, Noris; Salmerón, Jorge; Rüttimann, Ricardo; Tinoco, Juan Carlos; Rubio, Pilar; Núñez, Ernesto; Guerrero, Lourdes; Yarzábal, Juan Pablo; Damaso, Silvia; Tornieporth, Nadia; Sáez Llorens, Xavier; Vergara, Rodrigo F.; Vesikari, Timo; Bouckenooghe, Alain; Clemens, Ralf; De Vos, Béatrice; O'Ryan Gallardo, Miguel (Massachusetts Medical Soc, 2006-01-05)
      BACKGROUND: The safety and efficacy of an attenuated G1P[8] human rotavirus (HRV) vaccine were tested in a randomized, double-blind, phase 3 trial. METHODS: We studied 63,225 healthy infants from 11 Latin American ...